HARVARD BIOSCIENCE INC (HBIO) Fundamental Analysis & Valuation

NASDAQ:HBIO • US4169062043

Current stock price

6.86 USD
+0.08 (+1.18%)
Last:

This HBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HBIO Profitability Analysis

1.1 Basic Checks

  • In the past year HBIO has reported negative net income.
  • In the past year HBIO had a positive cash flow from operations.
  • In the past 5 years HBIO always reported negative net income.
  • HBIO had a positive operating cash flow in each of the past 5 years.
HBIO Yearly Net Income VS EBIT VS OCF VS FCFHBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • HBIO has a worse Return On Assets (-70.81%) than 91.23% of its industry peers.
  • HBIO's Return On Equity of -412.84% is on the low side compared to the rest of the industry. HBIO is outperformed by 89.47% of its industry peers.
Industry RankSector Rank
ROA -70.81%
ROE -412.84%
ROIC N/A
ROA(3y)-27.7%
ROA(5y)-17.96%
ROE(3y)-145.7%
ROE(5y)-90.12%
ROIC(3y)N/A
ROIC(5y)N/A
HBIO Yearly ROA, ROE, ROICHBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • With a decent Gross Margin value of 57.67%, HBIO is doing good in the industry, outperforming 71.93% of the companies in the same industry.
  • HBIO's Gross Margin has been stable in the last couple of years.
  • HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.6%
GM growth 5Y0.3%
HBIO Yearly Profit, Operating, Gross MarginsHBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HBIO Health Analysis

2.1 Basic Checks

  • HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HBIO has been increased compared to 1 year ago.
  • Compared to 5 years ago, HBIO has more shares outstanding
  • HBIO has a worse debt/assets ratio than last year.
HBIO Yearly Shares OutstandingHBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
HBIO Yearly Total Debt VS Total AssetsHBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • HBIO has an Altman-Z score of -2.02. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
  • HBIO has a worse Altman-Z score (-2.02) than 80.70% of its industry peers.
  • The Debt to FCF ratio of HBIO is 7.37, which is on the high side as it means it would take HBIO, 7.37 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 7.37, HBIO is doing good in the industry, outperforming 63.16% of the companies in the same industry.
  • HBIO has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
  • HBIO's Debt to Equity ratio of 2.61 is on the low side compared to the rest of the industry. HBIO is outperformed by 85.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 7.37
Altman-Z -2.02
ROIC/WACCN/A
WACC11.51%
HBIO Yearly LT Debt VS Equity VS FCFHBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • HBIO has a Current Ratio of 2.20. This indicates that HBIO is financially healthy and has no problem in meeting its short term obligations.
  • HBIO has a Current ratio (2.20) which is comparable to the rest of the industry.
  • HBIO has a Quick Ratio of 1.25. This is a normal value and indicates that HBIO is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of HBIO (1.25) is worse than 71.93% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.25
HBIO Yearly Current Assets VS Current LiabilitesHBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. HBIO Growth Analysis

3.1 Past

  • HBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -133.33%.
  • Looking at the last year, HBIO shows a decrease in Revenue. The Revenue has decreased by -8.06% in the last year.
  • Measured over the past years, HBIO shows a decrease in Revenue. The Revenue has been decreasing by -3.25% on average per year.
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-8.06%
Revenue growth 3Y-8.59%
Revenue growth 5Y-3.25%
Sales Q2Q%-3.34%

3.2 Future

  • The Earnings Per Share is expected to grow by 55.18% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 5.99% on average over the next years.
EPS Next Y-644.6%
EPS Next 2Y55.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.49%
Revenue Next 2Y5.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HBIO Yearly Revenue VS EstimatesHBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
HBIO Yearly EPS VS EstimatesHBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. HBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HBIO. In the last year negative earnings were reported.
  • Also next year HBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBIO Price Earnings VS Forward Price EarningsHBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

  • 94.74% of the companies in the same industry are more expensive than HBIO, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, HBIO is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.3
EV/EBITDA 10.56
HBIO Per share dataHBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • HBIO's earnings are expected to grow with 55.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.18%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HBIO Dividend Analysis

5.1 Amount

  • HBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HBIO Fundamentals: All Metrics, Ratios and Statistics

HARVARD BIOSCIENCE INC

NASDAQ:HBIO (4/24/2026, 8:00:01 PM)

6.86

+0.08 (+1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-12
Earnings (Next)04-30
Inst Owners51.08%
Inst Owner Change-98.39%
Ins Owners6.74%
Ins Owner Change1.48%
Market Cap30.66M
Revenue(TTM)86.55M
Net Income(TTM)-56.70M
Analysts80
Price Target6.12 (-10.79%)
Short Float %N/A
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-100%
Min EPS beat(2)-100%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-30.64%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-49.3%
EPS beat(12)4
Avg EPS beat(12)-42.66%
EPS beat(16)5
Avg EPS beat(16)-40.85%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.73%
Max Revenue beat(2)0.94%
Revenue beat(4)3
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)3
Avg Revenue beat(8)-3.14%
Revenue beat(12)4
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-4.33%
PT rev (1m)200%
PT rev (3m)200%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12000%
EPS NY rev (1m)-253.68%
EPS NY rev (3m)-1636.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF 6.3
P/OCF 4.56
P/B 2.23
P/tB N/A
EV/EBITDA 10.56
EPS(TTM)-0.2
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)1.09
FCFY15.87%
OCF(TTM)1.51
OCFY21.94%
SpS19.36
BVpS3.07
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -70.81%
ROE -412.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.67%
FCFM 5.62%
ROA(3y)-27.7%
ROA(5y)-17.96%
ROE(3y)-145.7%
ROE(5y)-90.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.6%
GM growth 5Y0.3%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 7.37
Debt/EBITDA 6.54
Cap/Depr 31.34%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion 122.66%
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.25
Altman-Z -2.02
F-Score4
WACC11.51%
ROIC/WACCN/A
Cap/Depr(3y)36.65%
Cap/Depr(5y)29.73%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-644.6%
EPS Next 2Y55.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.06%
Revenue growth 3Y-8.59%
Revenue growth 5Y-3.25%
Sales Q2Q%-3.34%
Revenue Next Year3.49%
Revenue Next 2Y5.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y91.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y366.92%
FCF growth 3YN/A
FCF growth 5Y-9.87%
OCF growth 1Y367.29%
OCF growth 3Y80.2%
OCF growth 5Y-6.33%

HARVARD BIOSCIENCE INC / HBIO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HBIO.


Can you provide the valuation status for HARVARD BIOSCIENCE INC?

ChartMill assigns a valuation rating of 3 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Overvalued.


What is the profitability of HBIO stock?

HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for HBIO stock?

The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -644.6% in the next year.